Skip to main content
  • Jardiance Flops in HF Trials; Mob of Lawyers Attacks Hospital; Pacemaker From Fat?

    Recent developments of interest in cardiovascular medicine

    SGLT2 diabetes drug empagliflozin (Jardiance) failed to improve exercise ability over placebo in chronic heart failure patients with or without diabetes in top-line data announced from the phase III trials Emperial-Reduced and Emperial-Preserved. (FiercePharma)

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details